Abemaciclib plus endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

被引：0

作者：

Johnston, S. ^{[1
]}

Toi, M. ^{[2
]}

O'Shaughnessy, J. ^{[3
]}

Rastogi, P. ^{[4
,5
]}

Campone, M. ^{[6
]}

Neven, P. ^{[7
]}

Huang, C. S. ^{[8
]}

Huober, J. ^{[9
]}

Jaliffe, G. Garnica ^{[10
]}

Cicin, I. ^{[11
]}

Tolaney, S. ^{[12
]}

Goetz, M. P. ^{[13
]}

Rugo, H. ^{[14
]}

Senkus, E. ^{[15
]}

Testa, L. ^{[16
]}

Del Mastro, L. ^{[17
]}

Shimizu, C. ^{[18
]}

Wei, R. ^{[19
]}

Shahir, A. ^{[19
]}

Munoz, M. ^{[19
]}

Antonio, B. San ^{[19
]}

Andre, V. ^{[19
]}

Harbeck, N. ^{[20
]}

Martin, M. ^{[21
]}

机构：

[1] Royal Marsden Hosp, London, England

[2] Kyoto Univ, Grad Sch Med, Kyoto, Japan

[3] Baylor Univ, Med Ctr, Dallas, TX USA

[4] Univ Pittsburgh, NSABP NRG Oncol, Pittsburgh, PA USA

[5] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[6] Inst Cancerol Ouest, St Herblain, France

[7] Univ Ziekenhuis Leuven, Leuven, Belgium

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Kantonsspital St Gallen, St Gallen, Switzerland

[10] Grp Med Camino SC, Mexico City, Mexico

[11] Trakya Univ, Fac Med, Edirne, Turkiye

[12] Dana Farber Canc Inst, Boston, MA USA

[13] Mayo Clin, Rochester, MN USA

[14] Univ Calif San Francisco, San Francisco, CA USA

[15] Med Univ Gdansk, Gdansk, Poland

[16] Inst Canc Estado Sao Paulo ICESP, Sao Paulo, Brazil

[17] Univ Genoa, IRCCS Osped Policlin San Martino, Genoa, Italy

[18] Natl Ctr Global Hlth & Med, Tokyo, Japan

[19] Eli Lilly & Co, Indianapolis, IN USA

[20] Univ Munich, Munich, Germany

[21] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

来源：

BREAST | 2023年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P017

引用

页码：S22 / S23

页数：2

共 28 条

[21] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Tolaney, Sara M.
Fallowfield, Lesley
Kaufman, Peter A.
Ciruelos, Eva M.
Gainford, Mary Corona
Lu, Yi
Hurt, Karla
Wasserstrom, Heather Ann
Chen, Yanyun
Goel, Shom
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Johnston, Stephen R. D.
Toi, Masakazu
O'Shaughnessy, Joyce
Rastogi, Priya
Campone, Mario
Neven, Patrick
Huang, Chiun-Sheng
Huober, Jens
Jaliffe, Georgina Garnica
Cicin, Irfan
Tolaney, Sara M.
Goetz, Matthew P.
Rugo, Hope S.
Senkus, Elzbieta
Testa, Laura
Del Mastro, Lucia
Shimizu, Chikako
Wei, Ran
Shahir, Ashwin
Munoz, Maria
San Antonio, Belen
Andre, Valerie
Harbeck, Nadia
Martin, Miguel
LANCET ONCOLOGY, 2023, 24 (01): : 77 - 90
[23] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes (vol 42, 10.1200/JCO.23.01994, 2024)
Rastogi, Priya
O'Shaughnessy, Joyce
Martin, Miguel
Boyle, Frances
Cortes, Javier
Rugo, Hope S.
Goetz, Matthew P.
Hamilton, Erika P.
Huang, Chiun-Sheng
Senkus, Elzbieta
Tryakin, Alexey
Cicin, Irfan
Testa, Laura
Neven, Patrick
Huober, Jens
Shao, Zhimin
Wei, Ran
Andre, Valerie
Munoz, Maria
San Antonio, Belen
Shahir, Ashwin
Harbeck, Nadia
Johnston, Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2111 - 2111
[24] Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes (vol 43, 10.1200/JCO-24-02469, 2024)
Rastogi, Priya
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (01) : 113 - 113
[25] Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib
Tripathy, Debu
Im, Seock-Ah
Colleoni, Marco
Franke, Fabio
Bardia, Aditya
Harbeck, Nadia
Hurvitz, Sara
Chow, Louis
Sohn, Joohyuk
Lee, Keun Seok
Campos-Gomez, Saul
Vazquez, Rafael Villanueva
Jung, Kyung Hae
Babu, K. Govind
Wheatley-Price, Paul
De laurentiis, Michelino
Im, Young-Hyuck
Kummel, Sherko
El-Saghir, Nagi
Liu, Mei-Ching
Kaur, Sharonjeet
Gasch, Claudia
Wang, Craig
Wang, Yongyu
Chakravartty, Arunava
Lu, Yen-Shen
Liu, Mei-Ching
CANCER RESEARCH, 2021, 81 (04)
[26] Efficacy analysis of CDK4/6 inhibitors (CDKi) plus endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study
Tolosa Ortega, Pablo
Pascual, Tomas
Hernando, Cristina
Servitja, Sonia
Fernandez-Abad, Maria
Braso-Maristany, Fara
Benitez Fuentes, Javier David
Lema, Laura
Parrilla Rubio, Lucia
Ruano, Yolanda
Maria Roncero, Ana
Sanchez-Bayona, Rodrigo
Alva Bianchi, Manuel
Villacampa, Guillermo
Cobos-Fernandez, Maria Angeles
del Rocio Moreno, Maria
Canes, Jordi
Salvador, Fernando
Prat, Aleix
Ciruelos, Eva M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA
Decker, Thomas
Brucker, Cosima
Engel, Anne
Fasching, Peter A.
Goehler, Thomas
Jackisch, Christian
Janssen, Jan
Koehler, Andreas
Luedtke-Heckenkamp, Kerstin
Lueftner, Diana
van Mackelenbergh, Marion
Marme, Frederik
Nusch, Arnd
Rautenberg, Beate
Reimer, Toralf
Schmidt, Marcus
Weide, Rudolf
Wimberger, Pauline
Roos, Christian
Woeckel, Achim
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.
Lueftner, Diana
Brucker, Cosima
Decker, Thomas
Fasching, Peter A.
Goehler, Thomas
Jackisch, Christian
Janssen, Jan
Koehler, Andreas
Luedtke-Heckenkamp, Kerstin
Van Mackelenbergh, Marion
Marme, Frederik
Nusch, Arnd
Rautenberg, Beate
Reimer, Toralf
Schmidt, Marcus
Weide, Rudolf
Wimberger, Pauline
Nabieva, Naiba
Roos, Christian
Woeckel, Achim
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 →